Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. However, up to 40–50% of GISTs develop secondary resistance after an average of 24 months of imatinib treatment. It has been reported that autophagy can promote the survival o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Song, Shu, Yefei, Lu, Yidan, Sun, Yangcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342409/
https://www.ncbi.nlm.nih.gov/pubmed/32753885
http://dx.doi.org/10.2147/OTT.S256935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342409/
https://www.ncbi.nlm.nih.gov/pubmed/32753885
http://dx.doi.org/10.2147/OTT.S256935

Ejemplares similares